The famhp is actively involved in the management of the Ebola dossier:
Read more on the role of the famhp.
More information on:
Le risque de pénurie d'électricité est réel cet hiver
Ensemble, nous pouvons faire la différence et minimiser le risque de coupure.
Tout simplement en réduisant - comme les autorités et de nombreuses entreprises - notre consommation personnelle.
Agissez surtout entre 17 et 20 heures pour limiter le pic de consommation quotidien.
Information for the public
A clear vision of the future - Annual report 2013
The annual report “A clear vision of the future – Annual report 2013” is available :
You can also ask for a paper copy of this annual report (as long as available) by mail to: email@example.com
The new edition of the electronic newsletter "VIG-NEWS" of the federal agency for medicines and health products (famhp) is now available. The VIG-NEWS is a selection of recent news concerning pharmacovigilance from different sources.read more
Due to an underemployment within the Call Center Registration in 2014, this resulted in a delay in the processing of the daily requests send to firstname.lastname@example.org. In the meantime the team has been expanded and a procedure has been worked out in order to absorb the delayed requests. As for the new requests, a workflow has been worked out in order to increase the efficiency.read more
Due to a reduction in the manufacturing capacity for the vaccines HAVRIX 1440 and HAVRIX JUNIOR 720 (GSK), used to protect adults and children against hepatitis A, and in order to limit the impact of these supply shortages, alternatives are being proposed The Superior Health Council (SHC) details the correct use of the proposed alternatives in advice number 9260: Recommendation concerning the risk on the shortage supply for hepatitis A vaccine.read more
Links to pages and documents useful for healthcare professionals
- Direct Healthcare Professional
- Field Safety Notices concerning
- Therapeutic Magistral Form (TMF)
- Unavailability of medicinal products
- RMA-materials (Risk Minimisation Activities)
- International Nonproprietary Name (INN) prescription and substitution
- Withdrawal periods (medicines for veterinary use)